Literature DB >> 9747728

Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.

M R Klein1, S H van der Burg, E Hovenkamp, A M Holwerda, J W Drijfhout, C J Melief, F Miedema.   

Abstract

HLA-B57 has been shown to be strongly associated with slow disease progression in human immunodeficiency virus type 1 (HIV-1)-infected patients from the Amsterdam Cohort. Since HIV-1-specific CTL can control and eliminate virus-infected cells, we sought to characterize the dominant HLA-B57-restricted CTL responses at the epitope level. It was found that HLA-B57-restricted CTL responses were targeted at multiple proteins of HIV-1, with CTL specific for Gag and RT being the most pronounced. Gag-specific CTL recognized peptides ISPRTLNAW (aa 147-155) and STLQEQIGW (aa 241-249), which had previously been reported as HLA-B57-restricted. The RT-specific CTL response in one long-term survivor studied in great detail persisted for > 10 years and was dominated by HLA-B57-restricted CTL that recognized the newly defined epitope IVLPEKDSW (RT(LAI), aa 244-252). This epitope could be recognized in the context of both HLA-B*5701 and HLA-B*5801. Interestingly, three epitope variants of IVLPEKDSW were observed, which coincided with the strongest detectable CTL response to RT. One variant (T2E7) was not recognized by IVLPEKDSW-specific CTL despite the fact that this variant bound to HLA-B*5701 with a similar affinity as the index peptide. Finally, only viruses which contained the epitope index sequence were obtained suggesting efficient virus control by CTL. In conclusion, we report the characterization of dominant HIV-1 Gag- and RT-derived, HLA-B57-restricted CTL epitopes which are associated with longer time to AIDS. Further characterization of CTL responses restricted by HLA-B57 and other protective HLA alleles may contribute to the development of effective AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747728     DOI: 10.1099/0022-1317-79-9-2191

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  36 in total

1.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The distribution of polymorphic Alu insertions within the MHC class I HLA-B7 and HLA-B57 haplotypes.

Authors:  David S Dunn; Brian D Tait; Jerzy K Kulski
Journal:  Immunogenetics       Date:  2004-12-08       Impact factor: 2.846

3.  HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children.

Authors:  Kumud K Singh; Ping Kathryn Gray; Yan Wang; Terence Fenton; Rodney N Trout; Stephen A Spector
Journal:  J Acquir Immune Defic Syndr       Date:  2011-05-01       Impact factor: 3.731

4.  Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

Review 5.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

6.  Dynamics and timing of in vivo mutations at Gag residue 242 during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Sikhulile Moyo; Rosemary Musonda; M Essex
Journal:  Virology       Date:  2010-05-04       Impact factor: 3.616

7.  Rapid evolution of HIV-1 to functional CD8⁺ T cell responses in humanized BLT mice.

Authors:  Timothy E Dudek; Daniel C No; Edward Seung; Vladimir D Vrbanac; Lena Fadda; Priyasma Bhoumik; Christian L Boutwell; Karen A Power; Adrianne D Gladden; Laura Battis; Elizabeth F Mellors; Trevor R Tivey; Xiaojiang Gao; Marcus Altfeld; Andrew D Luster; Andrew M Tager; Todd M Allen
Journal:  Sci Transl Med       Date:  2012-07-18       Impact factor: 17.956

8.  MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape.

Authors:  Phillip Pymm; Patricia T Illing; Sri H Ramarathinam; Geraldine M O'Connor; Victoria A Hughes; Corinne Hitchen; David A Price; Bosco K Ho; Daniel W McVicar; Andrew G Brooks; Anthony W Purcell; Jamie Rossjohn; Julian P Vivian
Journal:  Nat Struct Mol Biol       Date:  2017-02-20       Impact factor: 15.369

9.  Immunodominant HIV-1-specific HLA-B- and HLA-C-restricted CD8+ T cells do not differ in polyfunctionality.

Authors:  Nompumelelo Mkhwanazi; Christina F Thobakgale; Mary van der Stok; Shabashini Reddy; Zenele Mncube; Fundisiwe Chonco; Bruce D Walker; Marcus Altfeld; Philip J R Goulder; Thumbi Ndung'u
Journal:  Virology       Date:  2010-07-17       Impact factor: 3.616

10.  Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.

Authors:  David H O'Connor; Bianca R Mothe; Jason T Weinfurter; Sarah Fuenger; William M Rehrauer; Peicheng Jing; Richard R Rudersdorf; Max E Liebl; Kendall Krebs; Joshua Vasquez; Elizabeth Dodds; John Loffredo; Sarah Martin; Adrian B McDermott; Todd M Allen; Chenxi Wang; G G Doxiadis; David C Montefiori; Austin Hughes; Dennis R Burton; David B Allison; Steven M Wolinsky; Ronald Bontrop; Louis J Picker; David I Watkins
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.